MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies_Pain
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP)*
Organization & Developments: NRx Pharmaceuticals
Parents
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP)*
Children
*NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD.
*NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
*The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
2024: NRx Pharma Advances FDA Application for Groundbreaking Ketamine Depression Treatment
2024: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
2025: NRx Pharmaceuticals Acquires Premier Mental Health Clinic, Expands Veterans Care Network
Jumps
Finance & Acquisitions: NRx Pharmaceuticals
Key People: NRx Pharmaceuticals